The Illuminating the Druggable Genome (IDG) Program is now Accepting Applications!
Launched in 2014, the NIH Common Fund’s Illuminating the Druggable Genome (IDG) Program enables researchers to explore understudied proteins with the potential to be modified by medicines. IDG aims to catalyze the discovery of novel biology, with a particular focus on understudied members of the protein kinase, ion channel, and non-olfactory G-protein-coupled receptor (GPCR) families. The program is funded by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Center for Advancing Translational Sciences (NCATS), and National Cancer Institute (NCI): https://commonfund.nih.gov/idg/index.
IDG is now soliciting applications to be part of the IDG consortium. Note these are not SBIR/STTR solicitations, but small businesses are eligible and encouraged to apply. The program plans to allocate $54 million to advance research through the development, broad dissemination, and use of community scientific resources to study human proteins for which publicly available information or active research is lacking. Applications are due March 14, 2017. The protein targets that will be the initial focus of the IDG consortium can be found here.
For questions, please contact:
Jenna L. Baker, Ph.D.
Program Manager, Illuminating the Druggable Genome
National Institute of Diabetes and Digestive and Kidney Diseases
Building 2DEM, Room 6076
6707 Democracy Boulevard, Bethesda, MD 20892